Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing Anzhen Hospital
About this trial
This prospective observational study aims to investigate the association between risk factors and cognitive function in patients with coronary heart disease (CHD), and to explore the underlying mechanisms involving metabolic parameters and multimodal imaging features. A total of 2,352 participants will be enrolled from Beijing Anzhen Hospital, Capital Medical University, China. Eligible participants are adults (≥18 years) with confirmed CHD who undergo systematic neuropsychological assessment during hospitalization. Comprehensive assessments include cognitive function tests (MMSE, MoCA, BCAT, AD8), metabolic evaluations (fasting glucose, insulin, HbA1c, ceramides), coronary computed tomography angiography (CCTA), cardiac magnetic resonance (CMR), sleep respiratory monitoring, and frailty and psychological assessments.The primary outcome is cognitive impairment. The study will identify potential risk factors and provide insights into early identification and personalized intervention strategies for cognitive decline in CHD patients.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Coronary angiography or coronary CTA showing ≥50% stenosis in ≥1 major coronary artery;
Established diagnosis of coronary heart disease with prior medical, interventional, or surgical treatment;
Objective evidence of myocardial ischemia or typical clinical symptoms
Disqualifiers
Previously diagnosed dementia.
History of stroke, cerebral hemorrhage, or other central nervous system diseases known to cause cognitive impairment.
Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).
Pregnancy or breastfeeding.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
2,352 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov